Search

Your search keyword '"Benjamin P. Linas"' showing total 178 results

Search Constraints

Start Over You searched for: Author "Benjamin P. Linas" Remove constraint Author: "Benjamin P. Linas"
178 results on '"Benjamin P. Linas"'

Search Results

1. Long COVID impacts: the voices and views of diverse Black and Latinx residents in Massachusetts

2. Cost of start-up activities to implement a community-level opioid overdose reduction intervention in the HEALing Communities Study

3. Long COVID awareness and receipt of medical care: a survey among populations at risk for disparities

5. A study protocol for Project I-Test: a cluster randomized controlled trial of a practice coaching intervention to increase HIV testing in substance use treatment programs

6. At the intersection of trust and mistrust: A qualitative analysis of motivators and barriers to research participation at a safety‐net hospital

7. Modeling as Visioning: Exploring the Impact of Criminal Justice Reform on Health of Populations with Substance Use Disorders

8. 'Community members have more impact on their neighbors than celebrities': leveraging community partnerships to build COVID-19 vaccine confidence

9. The Determining Effective Testing in Emergency Departments and Care Coordination on Treatment Outcomes (DETECT) for Hepatitis C (Hep C) Linkage-to-Care Trial: rationale and design of an emergency department-based randomized clinical trial of linkage-to-care strategies for hepatitis C

10. The Determining Effective Testing in Emergency Departments and Care Coordination on Treatment Outcomes (DETECT) for Hepatitis C (Hep C) Screening Trial: rationale and design of a multi-center pragmatic randomized clinical trial of hepatitis C screening in emergency departments

11. The role of increasing pharmacy and community distributed naloxone in the opioid overdose epidemic in Massachusetts, Rhode Island, and New York City

12. Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge

13. Rationale, design, and methodology of a trial evaluating three models of care for HCV treatment among injection drug users on opioid agonist therapy

14. Economic evaluation of HCV testing approaches in low and middle income countries

15. Challenges of COVID-19 Case Forecasting in the US, 2020-2021.

17. Estimating Absenteeism Related to Nonalcohol Substance Use in a US National Cohort of Full-Time Employees

18. Medicaid Hepatitis C Virus Treatment Policies: Impact on Testing and Treatment in the Commercially Insured

19. Metamodeling for Policy Simulations with Multivariate Outcomes

20. Population‐level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost‐effectiveness analysis

21. Modeling the cost‐effectiveness and impact on fatal overdose and initiation of buprenorphine–naloxone treatment at syringe service programs

22. Variation in Initiation, Engagement, and Retention on Medications for Opioid Use Disorder Based on Health Insurance Plan Design

23. Nutritional Supplementation Would Be Cost-Effective for Reducing Tuberculosis Incidence and Mortality in India: The Ration Optimization to Impede Tuberculosis (ROTI-TB) Model

24. Laboratory test trends within 72 hours of hospital admission associated with death among COVID-19 patients

25. Projected Long-Term Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Hepatitis C Outcomes in the United States: A Modeling Study

27. The Hepatitis C Care Cascade During the Direct-Acting Antiviral Era in a United States Commercially Insured Population

28. Estimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts

29. Estimated Clinical Outcomes and Cost-effectiveness Associated With Provision of Addiction Treatment in US Primary Care Clinics

30. Determining the lower limit of detection required for HCV viral load assay for test of cure following direct-acting antiviral-based treatment regimens: Evidence from a global data set

31. Addressing Inequities in SARS-CoV-2 Vaccine Uptake: The Boston Medical Center Health System Experience

32. Evaluation of individual and ensemble probabilistic forecasts of COVID-19 mortality in the United States

33. Rapid Versus Laboratory-Based Testing for HIV and Hepatitis C at a Drug Detoxification Treatment Center: A Randomized Trial

34. HCV Testing and Treatment in a National Sample of US Federally Qualified Health Centers during the Opioid Epidemic

35. Possible N-methyl-D-aspartate receptor antibody-mediated encephalitis in the setting of HIV cerebrospinal fluid escape

36. Keep it Up! 3.0: Study Protocol for a Type III Hybrid Implementation-Effectiveness Cluster-Randomized Trial

37. Combination Therapy With Tocilizumab and Dexamethasone Cost-Effectively Reduces Coronavirus Disease 2019 Mortality

38. Resources Required for Implementation of SARS-CoV-2 Screening in Massachusetts K-12 Public Schools in Winter/Spring 2021

39. Community-based Naloxone Coverage Equity for the Prevention of Opioid Overdose Fatalities in Racial/Ethnic Minority Communities in Massachusetts and Rhode Island

40. Evaluating equity in community-based naloxone access among racial/ethnic groups in Massachusetts

41. Comparing Projected Fatal Overdose Outcomes and Costs of Strategies to Expand Community-Based Distribution of Naloxone in Rhode Island

42. Barriers to accessing treatment for substance use after inpatient managed withdrawal (Detox): A qualitative study

43. Changing Dynamics of COVID-19 in the U.S. with the Emergence of the Delta Variant: Projections of the COVID-19 Simulator

44. Model-estimated relationship between elementary school-related SARS-CoV-2 transmission, mitigation interventions, and vaccination coverage across community incidence levels

45. Clinical impact, costs, and cost-effectiveness of hospital-based strategies for addressing the US opioid epidemic: a modelling study

46. Time for a New Approach to Guidance for Human Immunodeficiency Virus and Hepatitis C Virus Testing Among Persons Who Inject Drugs

47. Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids

48. Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort

49. Sociodemographic factors and social determinants associated with toxicology confirmed polysubstance opioid-related deaths

50. Short-Term Effects and Long-Term Cost-Effectiveness of Universal Hepatitis C Testing in Prenatal Care

Catalog

Books, media, physical & digital resources